AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01955083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
Study NCT00690287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6370
Description: Oral single dose, o.d., b.i.d. and q.i.d., suspension
Study NCT00690287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02053662 — intervention group
Intervention type: PROCEDURE
Intervention: Sample Collection
Description: A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
Study NCT01272791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
Study NCT01272791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
Study NCT01650714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full thickness gastric biopsy
Study NCT01650714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full thickness gastric biopsy
Study NCT03395730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraumbilical vein injection oxytocin
Description: intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
Study NCT01815359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPIC with FUDR and Leucovorin
Study NCT03395730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placental cord drainage
Description: placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
Study NCT02638506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
Study NCT03395730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expectant managment of 3rd stage of labour
Description: Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
Study NCT00568477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabThera
Description: Rituximab (MabThera):~375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes
Study NCT05122117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methylene blue mediated Photodynamic therapy
Description: Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
Study NCT05122117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
Study NCT01564264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
Study NCT05122117 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal therapy
Description: A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
Study NCT04175067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
Study NCT04175067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
Study NCT02513758 — intervention group
Intervention type: OTHER
Intervention: sample
Description: Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
Study NCT01738113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain exercise
Description: 1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors
Study NCT01738113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercise
Description: 1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT03988192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOC analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry.
Study NCT03294733 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
Study NCT01354847 — intervention group
Intervention type: DEVICE
Intervention: Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)
Description: ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
Study NCT00766246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT00841828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT03451214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Zinc
Description: 4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
Study NCT02522715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study NCT00766246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
Study NCT00766246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
Study NCT02522715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT02522715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01243970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg \*~\* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg.
Study NCT01243970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. \*~\* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg.
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 16 mg po prior to the infusion of intralipid
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: 16 mg po prior to the infusion of intralipid
Study NCT02436356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteoprobe-Reference Point Indentation (RPI)
Description: Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
Study NCT02436356 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA) Scans
Description: Assessment of Fracture Risk
Study NCT02436356 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Determines bound water and pore water of bone.
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule prior to the infusion of intralipid/heparin
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule prior to the infusion of intralipid/heparin
Study NCT03941431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin granules
Description: Jueyin granules p.o. once a day for 8 weeks.
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid
Description: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Study NCT02638506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Salinex
Description: All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
Study NCT03185793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 5 weeks
Study NCT03185793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: 1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
Study NCT03941431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moving cupping therapy
Description: Moving cupping therapy three times per week for 8 weeks.
Study NCT03941431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB therapy
Description: NB-UVB phototherapy three times per week for 8 weeks.
Study NCT03941431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin placebo granules
Description: Jueyin placebo granules p.o. once a day for 8 weeks.
Study NCT03941431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moving cupping placebo therapy
Description: Moving cupping placebo therapy three times per week for 8 weeks.
Study NCT03941431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB placebo phototherapy
Description: NB-UVB placebo phototherapy three times per week for 8 weeks.
Study NCT03538158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
Study NCT03538158 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
Study NCT01537510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR - Study of Technology to Accelerate Research
Description: In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
Study NCT02365285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Description: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
Study NCT02110888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous peripheral nerve stimulation
Study NCT01537510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STAR - Study of Technology to Accelerate Research
Description: In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
Study NCT02110888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SCS Only
Study NCT04754568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role-playing instructional design
Description: 60 minute traditional role-playing with standardized patient
Study NCT03689270 — intervention group
Intervention type: PROCEDURE
Intervention: Subluxation
Description: One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
Study NCT03689270 — intervention group
Intervention type: PROCEDURE
Intervention: Divide and conquer
Description: Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
Study NCT04604028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide [Leavdo®]
Description: Complete remission and partial remission rate
Study NCT02582619 — intervention group
Intervention type: OTHER
Intervention: Focus groups, semistructured interviews and Delphi rounds
Study NCT04650685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel Salvadora persica toothbrush
Description: The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
Study NCT04650685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Salvadora persica (miswak) chewing stick
Description: The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
Study NCT04650685 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard toothbrush and toothpaste (control)
Description: The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
Study NCT01092572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin 40 mg per day orally for 12 weeks.
Study NCT01092572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 tablet once daily for 12 weeks
Study NCT03683680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPT Test
Description: molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
Study NCT03683680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLDN15/VIM Test
Description: molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
Study NCT02454140 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Fixed five-fraction stereotactic radiotherapy
Study NCT04286737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
Study NCT03825692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong Capsule
Description: Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
Study NCT03825692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zhizhu Kuanzhong Placebo Capsule
Description: Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
Study NCT03801746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Oral dose 300 mg